Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M. Cocco E, et al. Among authors: papadopoulos kp. Sci Signal. 2018 Oct 9;11(551):eaat9773. doi: 10.1126/scisignal.aat9773. Sci Signal. 2018. PMID: 30301790 Free PMC article.
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE Jr, Wang Z, Lee S, Jones SF, Infante JR. Papadopoulos KP, et al. Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8. doi: 10.1007/s00280-013-2267-x. Epub 2013 Aug 25. Cancer Chemother Pharmacol. 2013. PMID: 23975329 Free PMC article. Clinical Trial.
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM. Papadopoulos KP, et al. Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583798 Clinical Trial.
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA. Kinneer K, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131388
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM. Ou Y, et al. Among authors: papadopoulos kp. Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25. Br J Clin Pharmacol. 2019. PMID: 30428505 Free PMC article. Clinical Trial.
Future options for imatinib mesilate-resistant tumors.
Sankhala KK, Papadopoulos KP. Sankhala KK, et al. Among authors: papadopoulos kp. Expert Opin Investig Drugs. 2007 Oct;16(10):1549-60. doi: 10.1517/13543784.16.10.1549. Expert Opin Investig Drugs. 2007. PMID: 17922620 Review.
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. Shimizu T, et al. Among authors: papadopoulos kp. Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19. Clin Cancer Res. 2012. PMID: 22261800
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Patnaik A, et al. Among authors: papadopoulos kp. Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23. Cancer Discov. 2016. PMID: 27217383
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, Orford K, Aktan G, Ferron-Brady G, Ibrahim N, Gauvin J, Motwani M, Cornfeld M. Tolcher AW, et al. Among authors: papadopoulos kp. Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9. doi: 10.1007/s00280-014-2615-5. Epub 2014 Nov 25. Cancer Chemother Pharmacol. 2015. PMID: 25417902 Clinical Trial.
140 results